On April 8 (local time), Kylo-11 (LPA-siRNA), independently developed by Hygieia, a wholly-owned subsidiary of Sino Biopharmaceutical (1177.HK), achieved the enrollment of the first US patient in the United States for its Phase II clinical trial in patients with atherosclerotic cardiovascular diease (ASCVD) and elevated lipoprotein (a) [Lp(a)].

Opioid-induced constipation (OIC) is one of the most common symptoms in cancer patients, affecting approximately 60%-90% of cancer patients using opioids for pain relief.

Following its clinical trial approval in China this March, TQB3205, a Class 1 innovative oral Pan-KRAS inhibitor independently developed by Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical (1177.HK), received approval from the U.S. Food and Drug Administration (FDA) on April 4 (local time), to conduct clinical trials for advanced malignant tumors.

Recently, the internationally renowned consulting firm Citeline released the "Pharma R&D Annual Review 2026" and introduced a new, more precise analytical method to select the "Top 25 Global Pharmaceutical Companies by Pipeline Scale".

Recently, Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical (1177.HK), announced that the first patient has been enrolled in a Phase III clinical trial of the Class 1 new drug TQ-B3234 capsules (a MEK1/2 inhibitor) at Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (abbreviated as Shanghai Ninth People’s Hospital).

On the morning of March 30, the "Mong Kok Community Living Room," sponsored by a donation from Ms. Cheng Cheung Ling, President of the Hong Kong Chinese Friendship Association, President of Chia Tai Pharmaceutical Group, and Vice Chair of the Board of Directors of Sino Biopharmaceutical (1177.HK), officially opened. This marks another important addition to the HKSAR Government's "Community Living Room Pilot Scheme," bringing warm care and tangible support to grassroots families in the Yau Tsim Mong District.

Recently, a Phase III clinical trial (TQB2102-III-02) of TQB2102, a HER2 bispecific dual-epitope antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical (1177.HK), for HER2-positive advanced breast cancer, has completed full enrollment of all subjects.

On March 26, Sino Biopharm (1177.HK) released its 2025 annual results. Driven by the in-depth advancement of its comprehensive innovation and development strategy and the rapid volume growth of innovative products launched intensively over the past three years, the company has delivered impressive results of double-digit growth in both revenue and net profit for four consecutive reporting periods.

On March 22, the China Development Forum 2026 Annual Conference opened in Beijing. Qiang Li, a member of the Standing Committee of the Political Bureau of the CPC Central Committee and Premier of the State Council, attended the opening ceremony and delivered a keynote speech.

On March 23, MSCI (Morgan Stanley Capital International), an internationally authoritative index provider, released its latest Environmental, Social, and Governance (ESG) rating results.